Who is sponsoring NCT06268652?

NCT06268652 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT06268652?

Interventions in NCT06268652: Organoid-guided personalized treatment, Gemcitabine, Capecitabine, Vinorelbine, Eribulin.

What condition does NCT06268652 study?

NCT06268652 studies Breast Cancer, Refractory Breast Carcinoma.

Is NCT06268652 still recruiting?

NCT06268652 is currently recruiting now. Last updated 20 February 2024.

Last reviewed 2024-02-20 · How we verify

NCT06268652

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

Recruiting now Phase 3 Last updated 20 February 2024

What this trial tests

Phase 3 trial testing Organoid-guided personalized treatment in Breast Cancer in 302 participants. Currently enrolling.

Timeline

15 January 2024

Primary endpoint
15 February 2026

15 January 2028

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	302
Start date	15 January 2024
Primary completion	15 February 2026
Estimated completion	15 January 2028
Sites	1 location across China

Drugs / interventions tested

Organoid-guided personalized treatment
Gemcitabine (gemcitabine) — full drug profile →
Capecitabine (capecitabine) — full drug profile →
Vinorelbine (vinorelbine) — full drug profile →
Eribulin (ERIBULIN) — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Refractory Breast Carcinoma — all drugs for Refractory Breast Carcinoma →

Sponsor

Sun Yat-sen University

Who can join

18 and older, any sex, with Breast Cancer or Refractory Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multicenter, open-label, randomized phase III trial is designed to study the efficacy and safety of organoid-guided personalized treatment （OGPT）versus treatment of physician's choice (TPC) in previously treated refractory breast cancer.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735
Immune organoid for cancer immunotherapy.
Wang XH, Wang WY, Sun ZJ. · · 2025 · cited 2× · PMID 40698131 · DOI 10.1016/j.apsb.2025.04.031
Ex Vivo Intestinal Organoid Models: Current State-of-the-Art and Challenges in Disease Modelling and Therapeutic Testing for Colorectal Cancer.
Randall-Demllo S, Al-Qadami G, Raposo AE, Ma C, et al · · 2024 · cited 1× · PMID 39518102 · DOI 10.3390/cancers16213664
Engineering bone marrow in a dish-a bloody business: preclinical opportunities, translational use cases, and a call for consensus.
North D, Meaker GA, Khan AO. · · 2026 · PMID 41791669 · DOI 10.1016/j.jtha.2026.02.018

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06268652 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 20 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06268652.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing